Medulloblastoma (MB) comprises a biologically heterogeneous group of embryonal tumours
of the cerebellum. Four subgroups of MB have been described (WNT, sonic hedgehog …

Platinum‐induced peripheral neurotoxicity (PIPN) is a common side effect of platinum‐
based chemotherapy that may cause dose reduction and discontinuation, with oxaliplatin …

Critical discoveries over the past two decades have transformed our understanding of
medulloblastoma from a single entity into a clinically and biologically heterogeneous …

Opinion Statement Approximately 70% of newly diagnosed children with medulloblastoma
(MB) will be classified as “standard risk”: their tumor is localized to the posterior fossa, they …

Medulloblastoma is the most common malignant brain tumor of childhood. While prognosis
has significantly improved in the last decades with multimodal therapy including surgery …

Summary The European Association of Neuro-Oncology (EANO) and EUropean RAre
CANcer (EURACAN) guideline provides recommendations for the diagnosis, treatment, and …

Opinion statement Medulloblastoma (MB) is a malignant embryonal tumor of the posterior
fossa and is the most common type of brain cancer in pediatric patients. In contrast, adult MB …

Background Medulloblastoma in adult patients is rare, with 0.6 cases per million. Prognosis
depends on clinical factors and medulloblastoma entity. No prospective data on the …

Simple Summary Craniospinal irradiation (CSI) is the backbone of medulloblastoma
treatment and the first treatment to achieve a cure in many patients. Within the last decades …

Background Adult medulloblastoma is a potentially curable malignant entity with an
incidence of 0.5–1 per million. Valid data on prognosis, treatment, and demographics are …